Skip to main content

Virani Shafique's Form 4 filing

Recursion Pharmaceuticals, Inc. (RXRX) · filed Aug 17, 2023

Accession no.
0001209191-23-046424
Filed
Aug 17, 2023
Trade date
Aug 15, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $166.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Virani ShafiqueCIK 0001856081Officer (Chief Business Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2023Class A Common StockFTax withholdingDisposed−3,603$9.19−$33,111.57140,351Direct
Aug 15, 2023Class A Common StockMOption exerciseAcquired+18,000$2.22+$39,960158,351Direct
Aug 15, 2023Class A Common StockSSaleDisposed−18,000$9.25−$166,500140,351Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 15, 2023Class A Common StockMOption exerciseDisposed−18,000$0.00$0451,469Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)